EU Medicines Regulation Achievements: EMA’...

By HEOR Staff Writer

March 16, 2026

The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Urgent Call for Enhanced Precision Oncology Access in Europe
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation